Home › Trial NCT03113695
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome
- Trial IDNCT03113695
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorUniversity of California, San Diego
- Enrollment4
- Start date2017-12-20
- ConditionsRichter's Syndrome · CLL
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.